Lv21
194 积分 2022-03-06 加入
Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500)
1小时前
待确认
Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy
6天前
已完结
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
11天前
已完结
Discovery of novel co-degradation CK1α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia
12天前
已完结
CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers
18天前
已完结
Selective CDK2 Degradation via Noncanonical Recruitment
18天前
已完结
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
18天前
已完结
Antitumor activity of celecoxib with docetaxel on human triple-negative breast cancer cells
29天前
已完结
Resistance-centered pharmacology of DNA damage response-targeted therapy: Mechanisms, predictive biomarkers, and biomarker-guided adaptive treatment strategies in solid tumors
1个月前
已完结
Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan
3个月前
已完结
皖公网安备34019202002308
